Interspond LLC

1. Moderna TX, Inc. $11,085,860 604 payments
2. Amgen Inc. $9,063,918 57 payments
3. Eli Lilly and Company $7,865,186 211 payments
4. AbbVie, Inc. $4,609,932 1,229 payments
5. Sanofi US Services Inc. $4,428,854 537 payments
6. GlaxoSmithKline, LLC. $4,155,876 750 payments
7. Ucb SA $3,931,879 244 payments
8. Genentech, Inc. $3,237,404 429 payments
9. Genzyme Corporation $3,112,705 438 payments
10. Janssen Research & Development, LLC $2,389,415 322 payments

1. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight $7,171,165 12 payments
2. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $3,924,857 275 payments
3. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $2,438,621 136 payments
4. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $2,385,752 15 payments
5. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $2,173,736 40 payments
6. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $1,633,492 73 payments
7. Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $1,491,240 186 payments
8. A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis $1,453,823 153 payments
9. A Phase 3 Study to Compare the Efficacy and Safety of Gepotidacin With $1,308,918 166 payments
10. A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa $987,651 88 payments

1. Professional salary support $13,000 2 payments
2. Patient care $8,143 1 payment
3. Other $4,551 2 payments
4. Overhead $1,500 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.